Comments on: Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

Comments on: Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab https://9krapalm.com/ivonescimab-receives-nmpa-approval-for-first-line-treatment-of-pd-l1-positive-nsclc-based-on-breakthrough-head-to-head-phase-iii-trial-demonstrating-superior-efficacy-over-pembrolizumab/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Fri, 25 Apr 2025 17:47:03 +0000 hourly 1 https://wordpress.org/?v=7.0